TY  - EJOU
AU  - WANG, XIAOXIA 
AU  - YAO, ZHONGYUAN 
AU  - LIU, DI 
AU  - YU, CHUNHONG 
AU  - LI, HUI 

TI  - Current and future therapies for abnormal early embryogenesis with assisted reproductive technology
T2  - BIOCELL

PY  - 2022
VL  - 46
IS  - 8
SN  - 1667-5746

AB  - Each stage of embryonic development, including normal gamete maturation, fertilization, zygotic genome activation, and cleavage, is crucial for human reproduction. Early embryo arrest is a common phenomenon. It is estimated that about 40%–70% of human embryos are arrested at early developmental stages. However, the exact mechanism remains largely uncertain. Embryos can be investigated <i>in vitro</i> by way of the development of <i>in vitro</i> fertilization/intracytoplasmic sperm injection. In addition to iatrogenic factors related to abnormal oocyte/embryo development, multiple gene mutations have been found to be involved in such phenotypes. Based on the knowledge of known etiological factors, several therapies are proposed to improve clinical outcomes. Here, we shed light on current and potential therapies for treating these conditions through reviewing articles and combining with our clinical and research experience.
KW  - Oocyte maturation arrest; Preimplantation embryonic lethality; Gene mutation; Infertility; Embryo development

DO  - 10.32604/biocell.2022.019731